Susan G Komen  
I've Been Diagnosed With Breast Cancer Someone I Know Was Diagnosed Share Your Story Join Us And Stay Informed Donate To End Breast Cancer
    Home > Research & Grants > Grants Program > Research Grants > Research Grants Awarded

    Research Grants Awarded

    2003-2004 Grant Cycle : Research Grants Awarded

    Biology of Breast Cancer

    Characterizing Determinants of Tamoxifen Resistance in Human Breast Cancer: Role of CtIP (RBBP8)
    C. Marcelo Aldaz, PhD
    University of Texas M.D. Anderson Cancer Center

    $250,000


    Stromal Caveolin-1 Regulation of Breast Cancer Growth and Metastasis.
    Robin Anderson, PhD
    Peter MacCallum Cancer Centre

    $250,000


    Epigenetic Consequences of BRCA1: The Key to its Role as a Tumor Suppressor Gene in Human Breast Cancer
    Bradley Arrick, MD
    Trustees of Dartmouth College

    $250,000


    Mouse Models of Breast Cancer Based on Epigenetic Silencing of the Hic-1 and AP-2Ą Genes
    Stephen Baylin, MD
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

    $250,000


    Epithelial Dependence on the Vasculature
    Laura Benjamin, PhD
    Beth Israel Deaconess Medical Center

    $250,000


    BP1, a New Homeobox Gene: a Strong Potential Target for Therapy of Breast Cancer
    Patricia Berg, PhD
    George Washington University Medical Center

    $249,850


    Role of the Heparin-Binding Growth Factor, Pleiotrophin, in Breast Cancer Motility and Invasion
    Emma Bowden, PhD
    Georgetown University

    $250,000


    Ceramide Metabolism As Prognostic Marker Of Chemotherapy Responsiveness And Metastatic Potential In Breast Cancer
    Myles Cabot, PhD
    John Wayne Cancer Institute

    $250,000


    CBFA2T3 is a Novel Breast Cancer Tumour Suppressor Gene: Investigation as a Prognostic Marker and Development of Drug Targets.
    David Callen, PhD
    University of Adelaide

    $250,000


    Preclinical Models for Treatment of Residual Neoplastic Disease
    Lewis Chodosh, MD
    University of Pennsylvania School of Medicine

    $249,777


    Progesterone Receptors and Hormonal Prevention of Breast Cancer
    Orla Conneely, PhD
    Baylor College of Medicine

    $250,000


    Fibroblast Activation Protein-Alpha Activation of a Bacterial Toxin as Targeted “Anti-Stromal” Therapy for Breast Cancer
    Samuel Denmeade, MD
    The Johns Hopkins School of Medicine

    $250,000


    Defining the Role of the Ras Family RERG Protein in Breast Cancer
    Channing Der, PhD
    University of North Carolina at Chapel Hill

    $249,408


    The Role of Toll-Like Receptors in Breast Cancer
    Joseph DiDonato, PhD
    Cleveland Clinic Foundation

    $250,000


    Mechanism of BCAR1/p130Cas-Mediated Estrogen-Independent Proliferation of Breast Cancer Cells
    Lambert Dorssers, PhD
    Josephine Nefkens Institute, Erasmus MC

    $250,000


    SWI/SNF: Mediator of the ER+/PR-, Tamoxifen-Resistant Phenotype?
    Dorraya El-Ashry, PhD
    The Regents of the University of Michigan for

    $249,657


    Identification of Novel Genetic Factors Contributing to Clinical Phenotypes in Large Families with BRCA1 and BRCA2 Mutations
    Rachel Ellsworth, PhD
    Windber Research Institute

    $241,284


    Syndecan-1 in Stromal Fibroblasts of Breast Carcinomas
    Andreas Friedl, MD
    University of Wisconsin-Madison

    $250,000


    Regulation of Breast Cancer Metastasis by Slit
    Ramesh Ganju, PhD
    Beth Israel Deaconess Medical Center

    $250,000


    The Role of RASSF1A in Cell Cycle Control After DNA Damage
    Boning Gao, PhD
    University of Texas Southwestern Medical Center at Dallas

    $250,000


    Does BRCA2 Justify Prophylactic Mastectomy? Allele-Specific Methylation Markers of BRCA2 v. AS3 Losses in Breast Cancer
    Peter Geck, MD
    Tufts University School of Medicine

    $250,000


    Identification of Metastasis Associated Breast Cancer Genes Using a High-Resolution Whole Genome Approach
    Joseph Geradts, MD
    Duke University

    $250,000


    Characterization of Chromosomal Condensation Defects in Breast Cancer
    Henry Heng, PhD
    Wayne State University

    $250,000


    Identification of Collaborating Mutations in Brca1 and Brca2 Mouse Mammary Tumors by Genome-Wide Screening for Chromosomal Imbalances
    Jos Jonkers, PhD
    Netherlands Cancer Institute

    $250,000


    Prevention of Genome Instability in Breast Cancer by Dietary Antimutagens
    Catherine Klein, PhD
    NYU School of Medicine

    $199,859


    Stop Breast Cancer with 3-BrPA, a Recently Discovered Anti-Metabolite with Strong Inhibiting Activity Against Primary and Metastatic Liver Cancer.
    Young Ko, PhD
    Johns Hopkins University

    $250,000


    The Role of the Stroma in Carcinogenesis
    Maricel Maffini, PhD
    Tufts University School of Medicine

    $250,000


    Molecular Mechanisms and Therapeutic Implications of a Novel Bi-Directional Cross-Talk Between the Lipogenic Enzyme Fatty Acid Synthase (FAS) and the HER-2/neu Oncogene in Breast Cancer
    Javier Menendez, PhD
    Fundacio Privada D'Investigacio Biomedica de Girona

    $250,000


    Disruption of Breast Cancer Chemoresistance by the Translational Antagonist 4E-BP1: A Bitransgenic Mouse Model
    Vitaly Polunovsky, PhD
    University of Minnesota

    $250,000


    Earlier Detection of Primary and Recurrent Breast Cancer Using Autoantibodies
    John Robertson, MD
    The University of Nottingham

    $249,610


    A Murine Model of Breast Cancer-Associated Lymphedema: Genome-Wide Transcriptional Profiling for the Study of Lymphedema Pathobiology, Cellular Signaling Mechanisms and Mechanisms of Therapeutic Lymphangiogenesis
    Stanley Rockson, MD
    Stanford University School of Medicine

    $249,879


    Role of Progestins and Progesterone Receptors in Hormone-Dependent Human Breast Cancers
    Carol Sartorius, PhD
    University of Colorado Health Sciences Center

    $250,000


    Determining the Role of CD44 in Breast Cancer Metastasis To the Lung
    Joyce Schroeder, PhD
    University of Arizona

    $250,000


    BRMS1 Regulates Osteopontin Expression in Metastatic Breast Cancer
    Lalita Shevde-Samant, PhD
    University of South Alabama

    $250,000


    Directed Delivery of RNA Interference Strategies to Breast Malignancies
    Ernest Terwilliger, PhD
    Beth Israel Deaconess Medical Center

    $250,000


    The Cellular Basis of Pregnancy-Mediated Protection Against Breast Cancer
    Kay-Uwe Wagner, PhD
    University of Nebraska Medical Center

    $225,186


    Molecular Mechanism of Estrogen Antagonists induced Suppression of Breast Cancer
    Sheng Wang, PhD
    Boston University School of Medicine

    $249,810


    Origins of Mammary Tumor Stromal Cells
    Robert Weinberg, PhD
    Whitehead Institute for Biomedical Research

    $250,000


    Role of Retinoid X Receptor and its Ligand in Breast Cancer
    Xiao-kun Zhang, PhD
    The Burnham Institute

    $249,253


    Early Detections, Diagnosis, and Prognosis

    Nipple Aspirate Fluid Basic Fibroblast Growth Factor
    Mai Nguyen Brooks, MD
    UCLA

    $250,000


    JAB1-Mediated p27Kip1 Degradation as a Prognostic Factor and a Therapeutics Target for Breast Cancer
    Francois Claret, PhD
    M.D. Anderson Cancer Center

    $250,000


    Shc Signaling Proteins: Prognostic and Predictive Markers in Breast Cancer
    A. Raymond Frackelton, PhD
    Roger Williams Hospital

    $250,000


    Clinical Utility of Hypermethylated Genes in Primary Tumors and Body Fluids as Prognostic Markers of Breast Cancer Patients
    Dave Hoon, PhD
    John Wayne Cancer Institute

    $250,000


    Phosphopeptide Antibodies as Prognostic Indicators for Breast Cancer
    Andrew Laudano, PhD
    University of New Hampshire

    $246,000


    DNA Methylation Profiles for Diagnosis, Monitoring and Residual Disease Detection in Breast Cancer
    Victor Levenson, MD
    Northwestern University

    $250,000


    Prediction of Breast Cancer Outcome to Adjuvant Chemotherapy Using Expression Profiling
    Dennis Sgroi, MD
    Massachusetts General Hospital

    $249,999


    Computed Tomographic Prediction of Response to Treatment in Breast Cancer Induced Bone Metstasis
    Brian Snyder, MD
    Orthopedic Biomechanics Laboratory

    $250,000


    Etiology

    Genetic Basis of DNA Repair Deficiency in Sporadic Breast Cancer
    Stephen Grant, PhD
    University of Pittsburgh

    $249,498


    Role of Nitrites/Nitrates in the Etiology of Breast Cancer
    Mary Beth Martin, PhD
    Georgetown University

    $200,000


    Characterization of Immunosuppressive Properties Induced by Eukaryotic Vector-Mediated Expression of HERV Genes Derived from Human Breast Cancer Cells
    Feng Wang-Johanning, MD
    UT MD Anderson Cancer Center

    $249,936


    Prevention

    Molecular Targets of Breast Cancer Prevention by n-3 PUFAs
    Huseyin Aktas, DVM
    Harvard Medical School

    $250,000


    Role of Aromatase and COX-2 Inhibition in the Prevention of p53-Mediated Breast Cancer
    Richard Arenas, MD
    Baystate Medical Center

    $249,991


    A Novel Combinatorial Approach to Inhibit the Development of Mammary Cancer
    Sarma Dittakavi, PhD
    University of Toronto

    $249,858


    Anticancer and Chemopreventive Potential of Constituents of Black Cohosh on Breast Cancer
    Linda Einbond, PhD
    Columbia University College of Physicians and Surgeons

    $250,000


    Type-I and Type-II Anti-Tumor-Promotion Agents: Combinations of Tamoxifen, a New Retinoid, and Moderate Dietary Restriction in the Prevention of Experimental Breast Cancers
    Isao Eto, PhD
    The Board of Trustees of the University of Alabama for the University of Alabama at Birmingham

    $224,210


    Lipocortin/Annexin I as a Unique Target of Mechanism-Based Chemoprevention of Breast Cancer
    Fusao Hirata, MD
    Wayne State University

    $250,000


    Inhibition of the Breast Cancer Marker MUC1 by the Chemopreventative, Indole-3-Carbinol
    Insong Lee, PhD
    University of Maryland

    $249,555


    Optical Transillumination Spectroscopy For Monitoring Breast Cancer Risk Changes
    Lothar Lilge, PhD
    University Health Network

    $245,000


    Delivery of Recombinant Mucin 1(MUC1) Protein and MUC1 Cytotoxic T Cell Epitopes into the Cytoplasm of Antigen Presenting Cells Using a Membrane Permeable Peptide for the Immunotherapy of Breast Cancer
    Geoffrey Pietersz, PhD
    Burnet Institute

    $158,500


    Does RARbeta2 P2 Methylation Predict Short-Term Breast Cancer Risk?
    Victoria Seewaldt, MD
    Duke University

    $250,000


    Monitoring the Effectiveness of NSAIDs Chemoprevention in Breast Cancer Using the CD13/APN Cell Surface Peptidase
    Linda Shapiro, PhD
    University of Connecticut Health Center

    $250,000


    Targeting DNA polymerase ß and Base Excision Repair in Breast Cancer: Characterization of a Novel p53-Independent Anti-Tumor Response
    Robert Sobol, PhD
    University of Pittsburgh Cancer Institute

    $250,000


    Green Tea Intervention for Weight Gain Prevention among Women with Breast Cancer
    Cynthia Thomson, PhD
    University of Arizona

    $246,796


    Effects of Soy on Estrogen Insuficency-induced Tamoxifen-Nonresponsive Breast Cancer
    Jin-Rong Zhou, PhD
    Beth Israel Deaconess Medical Center

    $241,348


    Treatment

    A Novel Combination Approach of Anti-Her2/Neu and Anti-Prolactin for Breast Cancer
    Wen Chen, PhD
    Clemson University

    $250,000


    Genomic Consequences of Restoring p53 Transactivating Function with PRIMA-1 in Breast Cancer
    Sayed Daoud, PhD
    Washington State University

    $250,000


    Comparing a Plant Based Olive Oil Diet to a Conventional Diet in Women Diagnosed with Invasive Breast Cancer After the Age of 50 for Improvement in Biomarkers and Weight Loss
    Mary Flynn, PhD
    The Miriam Hospital, Providence, RI

    $248,772


    Radiosurgical Irradiation of the Tumor Bed for Early Stage Breast Cancers
    Lijun Ma, PhD
    UCSF Long Hospital

    $250,000


    A Novel Antiangiogenic and Antimetastatic Agent for Breast Cancer
    Francis Markland, PhD
    USC Keck School of Medicine

    $250,000


    Novel Breast Cancer Therapeutic Vectors Based on a Paramyxovirus Fusion Protein
    Griffith Parks, PhD
    Wake Forest University Health Sciences

    $201,755


    Inhibition of Breast Cancer Growth by a Novel Regulator of EGFR
    Arun Rishi, PhD
    Karmanos Cancer Institute, Wayne State University

    $250,000


    Immunogene Therapy of Breast Cancer
    Mark Smyth, PhD
    Peter MacCallum Cancer Centre

    $250,000


    Development of a Conditionally Replicative Adenovirus Targeted to HER-2/Neu-overexpressing Breast Cancer Through an Antisense Iron-responsive Element
    Shao-Chun Wang, PhD
    M. D. Anderson Cancer Center

    $250,000


    Overcoming Apoptosis-Resistance by Bcl-2/Bcl-xL-Bispecific Small Molecule Inhibitors as a Novel and Molecular Targeted Therapy for Breast Cancer
    Liang Xu, MD
    University of Michigan Medical School

    $249,999



    * Pending executed agreement